Enantioselective N-Demethylation and Hydroxylation of Sibutramine in Human Liver Microsomes and Recombinant Cytochrome P-450 Isoforms

REFERENCES

• Arterburn, D. E., Crane, P. K., and Veenstra, D. L. 2004. The efficacy and safety of sibutramine for weight loss: A systematic review. Arch. Intern. Med. 164: 994–1003.
   PubMed Web of Science ®Google Scholar
• Bae, S. K., Cao, S., Seo, K. A., Kim, H., Kim, M. J., Shon, J. H., Liu, K. H., Zhou, H. H., and Shin, J. G. 2008. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes. Drug Metab. Dispos. 36: 1679–1688.
   PubMed Web of Science ®Google Scholar
• Bae, J. W., Jang, C. G., and Lee, S. Y. 2011. Effects of clopidogrel on the pharmacokinetics of sibutramine and its active metabolites. J. Clin. Pharmacol. 51: 1704–1711.
   PubMed Web of Science ®Google Scholar
• Bodhankar, S. L., Thakurdesai, P. A., Singhal, S., and Gaur, V. 2007. Anorexic effect of (R)-sibutramine: Comparison with (RS)-sibutramine [corrected] and (S)-sibutramine. Indian J. Physiol. Pharmacol. 51: 175–178.
   PubMedGoogle Scholar
• Chen, J., Lu, W., Zhang, Q., and Jiang, X. 2003. Determination of the active metabolite of sibutramine by liquid chromatography-electrospray ionization tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 785: 197–203.
   PubMed Web of Science ®Google Scholar
• Chung, J. Y., Jang, S. B., Lee, Y. J., Park, M. S., and Park, K. 2011. Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. J. Clin. Pharmacol. 51: 53–59.
   PubMed Web of Science ®Google Scholar
• Connoley, I. P., Liu, Y. L., Frost, I., Reckless, I. P., Heal, D. J., and Stock, M. J. 1999. Thermogenic effects of sibutramine and its metabolites. Br. J. Pharmacol. 126: 1487–1495.
   PubMed Web of Science ®Google Scholar
• Ellison, C. A., Abou El-Ella, S. S., Tawfik, M., Lein, P. J., and Olson, J. R. 2012. Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers. J. Toxicol. Environ. Health A 75: 232–241.
   PubMed Web of Science ®Google Scholar
• Francia-Farje, L. A., Silva, D. S., Volpato, G. T., Fernandes, G. S., Carnietto, N., Cicogna, A. C., and Kempinas, W. de G. 2010. Sibutramine effects on the reproductive performance of pregnant overweight and non-overweight rats. J. Toxicol. Environ. Health A 73: 985–990.
   PubMed Web of Science ®Google Scholar
• Glick, S. D., Haskew, R. E., Maisonneuve, I. M., Carlson, J. N., and Jerussi, T. P. 2000. Enantioselective behavioral effects of sibutramine metabolites. Eur. J. Pharmacol. 397: 93–102.
   PubMed Web of Science ®Google Scholar
• Hirota, T., Eguchi, S., and Ieiri, I. 2013. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab. Pharmacokinet. 28: 28–37.
   PubMed Web of Science ®Google Scholar
• Hisaka, A., Ohno, Y., Yamamoto, T., and Suzuki, H. 2010. Prediction of pharmacokinetic drug–drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol. Ther. 125: 230–248.
   PubMed Web of Science ®Google Scholar
• Hwang, I. C., Park, J. Y., Ahn, H. Y., Kim, K. K., Suh, H. S., Ko, K. D., and Kim, K. A. 2014. Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: A crucial role for the CYP2B6*6 allele. Clin.Chim. Acta. 428: 77–81.
   PubMed Web of Science ®Google Scholar
• Kim, K. A., Song, W. K., and Park, J. Y. 2009. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin. Pharmacol.Ther. 86: 511–518.
   PubMed Web of Science ®Google Scholar
• Link, M., Hakala, K. S., Wsol, V., Kostiainen, R., and Ketola, R. A. 2006. Metabolite profile of sibutramine in human urine: A liquid chromatography-electrospray ionization mass spectrometric study. J. Mass Spectrom. 41: 1171–1178.
   PubMed Web of Science ®Google Scholar
• Luscombe, G. P., Hopcroft, R. H., Thomas, P. C., and Buckett, W. R. 1989. The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology 28: 129–134.
   PubMed Web of Science ®Google Scholar
• Mazur, C. S., Kenneke, J. F., Tebes-Stevens, C., Okino, M. S., and Lipscomb, J. C. 2007. In vitro metabolism of the fungicide and environmental contaminant trans-bromuconazole and implications for risk assessment. J. Toxicol. Environ. Health A 70: 1241–1250.
   PubMed Web of Science ®Google Scholar
• Niemi, M., Neuvonen, P. J., and Kivisto, K. T. 2001. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin. Pharmacol. Ther. 70: 58–65.
   PubMed Web of Science ®Google Scholar
• Niwa, T., Murayama, N., and Yamazaki, H. 2011. Stereoselectivity of human cytochrome P450 in metabolic and inhibitory activities. Curr. Drug Metab. 12: 549–569.
   PubMed Web of Science ®Google Scholar
• Pan, W., Bae, S. K., Shim, E. J., Park, S. E., Lee, S. S., Park, S. J., Yeo, C. W., Zhou, H. H., Shon, J. H., and Shin, J. G. 2013. Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism. Xenobiotica 43: 211–218.
   PubMed Web of Science ®Google Scholar
• Rajpoot, D. S., Prakash, A., Mandil, R., Rahal, A., and Garg, S. K. 2013. Differential modulation of xenobiotic-metabolizing enzymes in rats following single and concurrent exposure to chlorpyrifos, arsenic, and ascorbic acid. J. Toxicol. Environ. Health A 76: 1354–1365.
   PubMed Web of Science ®Google Scholar
• Richter, T., Murdter, T. E., Heinkele, G., Pleiss, J., Tatzel, S., Schwab, M., Eichelbaum, M., and Zanger, U. M. 2004. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther. 308: 189–197.
   PubMed Web of Science ®Google Scholar
• Seo, K. A., Lee, S. J., Kim, K. B., Bae, S. K., Liu, K. H., Kim, D. H., and Shin, J. G. 2012. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica 42: 278–284.
   PubMed Web of Science ®Google Scholar
• Shinde, D. D., Kim, H. S., Choi, J. S., Pan, W., Bae, S. K., Yeo, C. W., Shon, J. H., Kim, D. H., and Shin, J. G. 2013. Different effects of clopidogrel and clarithromycin on the enantioselective pharmacokinetics of sibutramine and its active metabolites in healthy subjects. J. Clin. Pharmacol. 53: 550–558.
   PubMed Web of Science ®Google Scholar
• Stock, M. J. 1997. Sibutramine: A review of the pharmacology of a novel anti-obesity agent. Int. J. Obes. Related Metab. Disorders 21(suppl. 1): S25–S29.
   Google Scholar
• Suzuki, H., Kneller, M. B., Haining, R. L., Trager, W. F., and Rettie, A. E. 2002. (+)-N-3-Benzyl-nirvanol and (–)-N-3-benzyl-phenobarbital: New potent and selective in vitro inhibitors of CYP2C19. Drug Metab. Dispos. 30: 235–239.
   PubMed Web of Science ®Google Scholar
• Ueng, Y. F., Kuwabara, T., Chun, Y. J., and Guengerich, F. P. 1997. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36: 370–381.
   PubMed Web of Science ®Google Scholar
• Yu, L., Qian, M., Liu, Y., Yao, T., and Zeng, S. 2010. Stereoselective metabolism of propranolol glucuronidation by human UDP-glucuronosyltransferases 2B7 and 1A9. Chirality 22: 456–461.
   PubMed Web of Science ®Google Scholar
• Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., Hofmann, M. H., and Schwab, M. 2007. Polymorphic CYP2B6: Molecular mechanisms and emerging clinical significance. Pharmacogenomics 8: 743–759.
   PubMed Web of Science ®Google Scholar